Audentes Therapeutics to Participate in Upcoming November 2018 Investor Conferences

November 7, 2018 |

2 min read

Audentes Therapeutics, Inc. today announced that it will participate in the following investor conferences in November:

SAN FRANCISCO, Nov. 7, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in the following investor conferences in November:

Credit Suisse 27th Annual Healthcare Conference
Natalie Holles, President and Chief Operating Officer
Format: 1x1 Investor Meetings
Wednesday, November 14, 2018
Scottsdale, Arizona
Evercore ISI HealthConX Conference
Matthew R. Patterson, Chairman and Chief Executive Officer
Format: Fireside Chat
Tuesday, November 27, 2018, 10:35am EST
Boston, Massachusetts
Piper Jaffray 30th Annual Healthcare Conference
Matthew R. Patterson, Chairman and Chief Executive Officer
Format: Fireside Chat
Wednesday, November 28, 2018, 11:30am EST
New York, New York
Barclays Gene Editing & Gene Therapy Summit
Matthew R. Patterson, Chairman and Chief Executive Officer
Format: Corporate Presentation
Thursday, November 29, 2018, 10:15am EST
New York, New York

To access live webcasts of the fireside chats and presentation please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following each conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases. We are currently conducting Phase 1/2 clinical studies of our lead product candidates, AT132 for the treatment of X-linked myotubular myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar syndrome. We have two additional product candidates in development, including AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com

Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com

Audentes Therapeutics, Inc. (PRNewsfoto/Audentes Therapeutics, Inc.)